GTC's Nasdaq listing at risk - update
This article was originally published in Scrip
Executive Summary
GTC Biotherapeutics' listing on the Nasdaq capital market is under threat after its share price continued to trade below the minimum listing requirement of $1. The capital market requires a minimum market capitalisation of $35 million as opposed to the $50 million required by the global market.